Harrow Health, Inc. (HROW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Harrow Health, Inc. (HROW) Healthcare & Pipeline Overview

Harrow Health, Inc. is an ophthalmic-focused healthcare company specializing in pharmaceutical compounding and outsourcing through its ImprimisRx business. It differentiates itself by holding equity interests in companies developing therapeutics for ocular surface diseases and non-intravenous sedation, positioning it uniquely within the specialty drug manufacturing sector.

What Is the Investment Thesis for HROW?

Harrow Health presents a compelling, albeit speculative, investment thesis centered on its unique position within the ophthalmic pharmaceutical market. The company's ImprimisRx compounding business provides a stable revenue base, while its equity stakes in Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals offer potential upside through successful drug development and commercialization. Key value drivers include the continued growth of ImprimisRx, successful clinical trials and regulatory approvals for its portfolio companies, and potential royalty income from clinical-stage drug candidates. The company's gross margin of 75.1% indicates strong pricing power and efficient operations. Upcoming catalysts include clinical trial readouts from Surface Ophthalmics and Melt Pharmaceuticals. Potential risks include regulatory hurdles, competition from established pharmaceutical companies, and the inherent uncertainty associated with drug development.

Based on FMP financials and quantitative analysis

HROW Key Highlights

Market capitalization of $1.36B reflects investor confidence in Harrow Health's growth potential and strategic direction within the ophthalmic pharmaceutical market.

• Gross margin of 75.1% indicates strong pricing power and efficient operations in its pharmaceutical compounding business.
• Harrow Health holds equity interests in multiple clinical-stage pharmaceutical companies, providing exposure to innovative therapies and potential revenue streams.
• The company owns royalty rights in four clinical-stage drug candidates, offering potential upside through successful drug development and commercialization.
• Harrow Health's beta of 0.31 suggests lower volatility compared to the broader market, potentially appealing to risk-averse investors.

Who Are HROW's Competitors?

HROW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are HROW's Key Strengths?

Specialized focus on ophthalmic pharmaceuticals.

• Strong gross margin of 75.1%.
• Equity investments in innovative companies.
• Royalty rights in clinical-stage drug candidates.

What Are HROW's Weaknesses?

Reliance on regulatory approvals for portfolio companies.

• Competition from established pharmaceutical companies.
• Negative profit margin of -1.9%.
• Dependence on key personnel.

What Could Drive HROW Stock Higher?

Clinical trial results from Surface Ophthalmics for ocular surface disease therapeutics.

• Clinical trial results from Melt Pharmaceuticals for non-intravenous sedation therapeutics.
• Expansion of ImprimisRx compounding business through new formulations and partnerships.
• Potential acquisitions of complementary businesses or technologies.
• Regulatory approvals for drug candidates in Harrow Health's portfolio.

What Are the Key Risks for HROW?

Negative return on equity (-33.7%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Regulatory setbacks or delays in clinical trials for portfolio companies.
• Competition from established pharmaceutical companies with greater resources.
• Product liability claims related to compounded medications or other products.
• Economic downturns affecting healthcare spending and demand for elective procedures.
• Dependence on key personnel and potential loss of leadership.

What Are the Growth Opportunities for HROW?

• Expansion of ImprimisRx: Harrow Health can expand its ImprimisRx compounding business by increasing its market share within the ophthalmic pharmaceutical market. The market for compounded medications is estimated at several billion dollars annually, offering significant growth potential. This expansion can be achieved through targeted marketing efforts, strategic partnerships with ophthalmologists and clinics, and the introduction of new compounded formulations. Timeline: Ongoing.
• Successful Clinical Trials: Harrow Health's equity investments in Surface Ophthalmics and Melt Pharmaceuticals provide exposure to potential blockbuster drugs. Positive clinical trial results and subsequent regulatory approvals could generate substantial returns for Harrow Health through increased equity value and royalty income. The market for ocular surface disease therapeutics is estimated at over $2 billion, while the market for non-intravenous sedation therapeutics is also significant. Timeline: 2026-2028.
• Geographic Expansion: Harrow Health can expand its geographic reach by entering new markets and regions. The global ophthalmic pharmaceutical market is growing, particularly in emerging economies. By establishing partnerships with local distributors and regulatory experts, Harrow Health can tap into these new markets and increase its revenue base. Timeline: 2027-2030.
• Acquisitions: Harrow Health can pursue strategic acquisitions to expand its product portfolio and market presence. By acquiring complementary businesses or technologies, Harrow Health can strengthen its competitive position and accelerate its growth. Potential acquisition targets include other compounding pharmacies, specialty pharmaceutical companies, and ophthalmic device manufacturers. Timeline: Ongoing.
• New Product Development: Harrow Health can invest in new product development to address unmet needs in the ophthalmic pharmaceutical market. This can involve developing new formulations of existing drugs, creating novel drug delivery systems, or identifying new therapeutic targets. The market for innovative ophthalmic therapies is substantial, offering significant growth potential for Harrow Health. Timeline: Ongoing.

What Are HROW's Competitive Advantages?

• Specialized Focus: Harrow Health's focus on ophthalmic pharmaceuticals and compounding provides a competitive advantage in a niche market.
• Equity Investments: The company's equity stakes in innovative companies offer potential upside and diversification.
• Royalty Rights: Ownership of royalty rights in clinical-stage drug candidates provides a recurring revenue stream.
• Proprietary Formulations: ImprimisRx's customized formulations offer a differentiated product offering.

What Does HROW Do?

Harrow Health, Inc., established in 2006 and headquartered in Nashville, operates as an ophthalmic-focused healthcare company. Originally incorporated as Imprimis Pharmaceuticals, Inc., the company rebranded to Harrow Health, Inc. in December 2018 to reflect its broader strategic vision. Harrow Health's core business revolves around addressing unmet needs in the ophthalmology sector through its ImprimisRx business, which focuses on pharmaceutical compounding and outsourcing services. ImprimisRx provides customized medications to meet specific patient needs, offering an alternative to traditional, mass-produced pharmaceuticals. In addition to ImprimisRx, Harrow Health holds equity interests in several clinical-stage pharmaceutical companies, including Surface Ophthalmics, Inc., which develops therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., focused on non-intravenous sedation and anesthesia therapeutics; and Eton Pharmaceuticals, Inc., which develops and commercializes drug products. Harrow Health also owns royalty rights in clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals, further diversifying its revenue streams and exposure to innovative therapies. DEXYCU, a treatment for post-operative inflammation, is also a key product in Harrow Health's portfolio. With a focus on innovation and specialized pharmaceutical solutions, Harrow Health aims to address critical gaps in ophthalmic care and related therapeutic areas.

What Products and Services Does HROW Offer?

• Operates ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business.
• Provides customized medications to meet specific patient needs.
• Holds equity interests in Surface Ophthalmics, Inc., focusing on ocular surface diseases.
• Holds equity interests in Melt Pharmaceuticals, Inc., focusing on non-intravenous sedation therapeutics.
• Holds equity interests in Eton Pharmaceuticals, Inc., developing and commercializing drug products.
• Owns royalty rights in clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals.
• Markets DEXYCU for the treatment of post-operative inflammation.

How Does HROW Make Money?

• Generates revenue through the sale of compounded medications and outsourced pharmaceutical services via ImprimisRx.
• Realizes gains from equity investments in clinical-stage pharmaceutical companies through increased valuation or potential acquisitions.
• Receives royalty payments from the commercialization of drug candidates developed by Surface Ophthalmics and Melt Pharmaceuticals.

What Industry Does HROW Operate In?

Harrow Health operates within the specialty pharmaceutical industry, which is characterized by a focus on niche markets and specialized drug formulations. The ophthalmic pharmaceutical market is experiencing growth driven by an aging population and increasing prevalence of eye diseases. Competition includes both established pharmaceutical companies with ophthalmic divisions and smaller, specialized players. Harrow Health differentiates itself through its compounding business, equity investments in innovative companies, and royalty rights in clinical-stage drug candidates. The industry is subject to stringent regulatory requirements and faces ongoing pressure to control drug prices.

Who Are HROW's Key Customers?

• Ophthalmologists and other healthcare providers who prescribe compounded medications for their patients.
• Hospitals and surgical centers that utilize DEXYCU for post-operative inflammation treatment.
• Patients who require customized medications to address specific ophthalmic conditions.

Company Profile

Harrow Health, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Nashville, United States.

Return on equity for Harrow Health, Inc. stands at -33.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.

HROW Valuation & Market Position

With a $1.36B market cap, Harrow Health, Inc. sits in the small-cap segment of the market. Analyst price targets span from $45.00 to $88.00, with a consensus of $65.33. At the current price of $36.58, that implies approximately 79% upside potential. Relative to its peer group, HROW's quantitative score of 52/100 is below the peer average of 75/100.

Quarterly Financial Performance: Harrow Health, Inc.

Revenue for Harrow Health, Inc. came in at $70.7M during Q2 FY2026, a 59.9% improvement versus the preceding quarter. The company recorded a net loss of $17.3M, with diluted EPS of $-0.46. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, HROW averaged $-0.25 in diluted EPS.

Harrow Health, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.36 places it in the grey zone, a middle ground that warrants monitoring.

Harrow Health, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 145.5% below estimates on average.

Over the past six months, Harrow Health, Inc. insiders filed 11 SEC Form 4 transactions — 2 sales and 9 purchases. On net that is roughly 30K shares acquired (about $19K) — insiders putting money in tends to read as conviction.

HROW Financials

HROW Latest News

HROW Analyst Consensus

HROW MoonshotScore

Common Questions About HROW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources